Literature DB >> 1965429

Multiple effects of increases in phosphoinositide hydrolysis on islets and their relationship to changing patterns of insulin secretion.

W Zawalich1.   

Abstract

Evidence continues to accumulate which suggests that increases in phosphoinositide hydrolysis play an integral role in beta cell insulin secretory response patterns. In the present report some of the methodological approaches utilized to monitor phosphoinositide-hydrolysis in islets are reviewed. The contribution of phosphoinositide-derived second messenger molecules to acute insulin release as well as the induction of time dependent potentiation are also discussed. Finally, the role of impaired phosphoinositide hydrolysis in the induction of time dependent suppression of insulin release is also explored. It is concluded that alterations in phosphoinositide hydrolysis contribute, at least in part, to both ordered and disordered patterns of insulin release noted under a variety of experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1965429

Source DB:  PubMed          Journal:  Diabetes Res        ISSN: 0265-5985


  4 in total

1.  Enhanced activation of phospholipase C and insulin secretion from islets incubated in fatty acid-free bovine serum albumin.

Authors:  Walter S Zawalich; Kathleen C Zawalich
Journal:  Metabolism       Date:  2008-02       Impact factor: 8.694

Review 2.  Genetic influences on glucose neurotoxicity, aging, and diabetes: a possible role for glucose hysteresis.

Authors:  C V Mobbs
Journal:  Genetica       Date:  1993       Impact factor: 1.082

3.  Effects of short-term culturing on islet phosphoinositide and insulin secretory responses to glucose and carbachol.

Authors:  W S Zawalich; K C Zawalich; G G Kelley
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

4.  Effects of prior 5-hydroxytryptamine exposure on rat islet insulin secretory and phospholipase C responses.

Authors:  Walter S Zawalich; Gregory J Tesz; Kathleen C Zawalich
Journal:  Endocrine       Date:  2004-02       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.